# ALCON INC (ALC) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-12  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ALC/thesis · /stocks/ALC/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: ALC
step: "04"
title: Financial Quality & Adversarial Sweep
created: 2026-06-11
---

### Step 04 — Financial Quality & Adversarial Sweep: Alcon Inc. (ALC)

#### 1. Statement Quality Assessment [S1]

##### Accounting Standards & Filing Structure
- Alcon reports under **IFRS** (not US-GAAP) as a Swiss foreign private issuer
- Annual 20-F filings; semi-annual 6-K (H1 only) — **no quarterly 10-Q equivalent**
- KPMG serves as independent auditor (Swiss entity)
- No restatements or material weaknesses identified in the filing inventory

##### Revenue Recognition Quality
- Revenue recognition under IFRS 15 (point-in-time for product sales; over-time for service/maintenance contracts)
- Surgical equipment: recognized on delivery/installation + commissioning acceptance
- Consumables: recognized on shipment or delivery
- **No concerns:** Revenue recognition is straightforward for a medical device company; no complex multi-element arrangements that would suggest manipulation risk

##### Quality Adjustments Required

| Item | GAAP Treatment | Adjusted View | Impact |
|------|---------------|--------------|--------|
| Intangible amortization (spin-off step-up) | Expensed through P&L (~$900M–1,000M/yr) | Add-back to get cash earnings | +$900M+ to "core" earnings |
| Restructuring/one-time charges | Variable: FY2025 includes operational efficiency program | Exclude for run-rate | +$50–100M |
| SBC | Expensed; non-cash | Non-cash; add back to FCF | +$162M (FY2025) |
| Acquisition-related intangibles (LumiThera, Aurion) | Amortized over 5–15 years | Part of ongoing D&A | Immaterial vs. spin-off step-up |

**Core EPS (non-GAAP) vs. GAAP EPS:**
- GAAP diluted EPS FY2025: $1.98
- Core (non-GAAP) diluted EPS FY2025: $3.07 [S2]
- Difference: +$1.09/share = ~55% uplift; primarily intangible amortization add-back
- This is a legitimate and widely-used adjustment in MedTech; peer companies (Bausch+Lomb, Zimmer) do the same

##### Working Capital Analysis

| Metric | FY2023 | FY2024 | FY2025 |
|--------|--------|--------|--------|
| Accounts Receivable | $1,770M | $1,736M | $1,942M |
| Days Sales Outstanding (DSO) | ~68d | ~64d | ~68d |
| Inventory | $2,322M | $2,268M | $2,391M |
| Days Inventory Outstanding (DIO) | ~201d | ~188d | ~188d |
| Accounts Payable | ~$600–700M | ~$600–700M | ~$600–700M |
| Days Payable Outstanding (DPO) | ~55–60d | ~55–60d | ~55–60d |

**DIO of ~188–200 days is elevated** but characteristic of medical device manufacturers with: (a) safety stock requirements for life-critical surgical consumables, (b) manufacturing lead times for precision optical components, and (c) global distribution complexity. This is not a quality concern.

FCF inflection (FY2023: $730M → FY2024: $1,604M → FY2025: $1,728M) is primarily driven by:
1. Working capital improvement: capex normalization ($658M → $473M/FY2024 reduction)
2. Operating income growth: EBIT from $1,039M → $1,413M (FY2024)
3. FY2025: continued operating cash flow improvement to $2,271M

This FCF inflection appears sustainable — capex $473–543M is the new normal vs. the $700M elevated spend during the integration/investment phase.

---

#### 2. Balance Sheet Quality [S1]

| Metric | FY2025 | Assessment |
|--------|--------|-----------|
| Goodwill | $9,256M | Stable; no impairment in last 3 years |
| Intangibles (ex-goodwill) | $9,006M | Amortizing normally; ~$900M+/yr amortization run-rate |
| Total intangible/goodwill as % of assets | 58% | **High** — characteristic of Novartis spin-off step-up; not a manipulation signal |
| Net Debt | $3,639M | ~1.4x LTM EBITDA — manageable leverage |
| LT Debt | $4,162M | Predominantly senior notes; no near-term maturity cliff |
| Shareholders' Equity | $22,035M | Growing steadily; net income + SBC accumulation |

**Goodwill impairment risk:** Alcon tests goodwill annually under IFRS IAS 36. The surgical CGU carries the majority of goodwill. With EBIT margins improving and FCF inflecting, there is no indication of near-term impairment risk. However, a sustained ATIOL market share loss would be the trigger to watch.

---

#### 3. Cash Flow Quality

| Metric | FY2023 | FY2024 | FY2025 | Notes |
|--------|--------|--------|--------|-------|
| Operating CFO | $1,388M | $2,077M | $2,271M | Strong; driven by net income + D&A |
| Capex | $658M | $473M | $543M | Normalized; FY2021–2023 was elevated investment period |
| FCF | $730M | $1,604M | $1,728M | Inflection is real and structural |
| FCF conversion (FCF/Net Income) | 75% | 157% | 176% | FCF > net income because D&A >> capex |
| FCF / EBITDA | 32% | 61% | 68% | Improving; tax payments and interest reduce from EBITDA |

FCF > net income is the hallmark of this business model: D&A of $1.2B/yr (primarily non-cash intangible amortization) far exceeds capex of $473–543M, creating significant cash generation above reported earnings.

---

#### 4. Adversarial Research Sweep [S3]

##### Short Thesis Review
No major dedicated short thesis was identified for Alcon. Key bearish concerns circulating in the investment community (per analyst research and press) include:

**1. ATIOL Market Share Loss to J&J Vision Sampling**
- J&J Vision has been aggressively sampling its Tecnis SYNERGY/SYMPHONY IOLs to surgeons, creating pricing and market confusion
- Concern: Alcon losing US premium IOL market share from ~52–55% to ~45–48%
- Assessment: **Legitimate risk, but not catastrophic.** Alcon's installed base (AcrySof is the most trained/implanted IOL globally), its broader portfolio (Clareon, PanOptix, Vivity cover different patient phenotypes), and its equipment bundling advantage limit the damage. The IOL market is growing: even if share is flat, volume growth sustains revenue growth.

**2. China VBP (Volume-Based Procurement) Pricing Pressure**
- China VBP IOL program (2021+) drove standard IOL pricing down ~80%; premium ATIOLs partially exempted
- Concern: Premium ATIOLs eventually swept into VBP; ASP erosion in China accelerates
- Assessment: **Ongoing but manageable.** Alcon's China business is growing in volume, offsetting price. Government is slowly rolling VBP to other categories but premium IOLs have so far been treated differently.

**3. Consensus Optimism on FY2026 Recovery Timing**
- BofA Underperform (issued Nov 2025): argues consensus overestimates the timing of ATIOL market recovery; sub-10% EPS CAGR is not worth ~25x earnings
- Concern: Q1 2026 EBIT margin (10.8%) already below FY2024 peak (14.3%), and without a clear ATIOL recovery timeline, multiple compression is likely
- Assessment: **This is the primary bear case.** It requires monitoring Q2–Q4 2026 ATIOL dynamics.

**4. Tariff Headwind ($100–150M)**
- Alcon manufactures in Belgium, Germany, and China and imports to the US; tariffs are a real cost
- Concern: $100–150M FY2026 headwind offsets operating leverage
- Assessment: **Disclosed, quantified, and manageable.** Alcon raised guidance in May 2026 despite the tariff headwind, suggesting underlying business momentum is absorbing it.

##### Legal / Regulatory Review
- No material active litigation disclosed in the filing inventory
- No SEC/DOJ investigations
- CyPass Micro-Stent withdrawal (2018) was a past product safety issue; fully resolved and not an ongoing exposure
- Standard product liability exposure typical of medical device companies

##### Accounting Red Flags Check
- ✅ No revenue recognition anomalies
- ✅ No sudden receivables build (DSO stable ~64–68 days)
- ✅ No unusual related-party transactions (Novartis relationship wound down post-spin)
- ✅ Auditor (KPMG Switzerland) continuous; no auditor changes
- ✅ No restatements
- ⚠️ High intangibles/goodwill (58% of assets) — **structural, not a red flag; disclosed and well-understood**
- ⚠️ Q1 2026 EBIT margin compression (-810 bps YoY) — needs monitoring; appears driven by other operating expenses timing/one-time items

---

#### 5. Financial Quality Summary

**Overall assessment: HIGH QUALITY**

Alcon is a well-run, transparent company with clean accounting, improving FCF, and no indication of earnings manipulation. The primary financial quality nuance is the IFRS amortization drag creating a persistent gap between GAAP earnings and cash earnings — this is structural and well-disclosed, not a red flag. The FCF inflection (FY2023→FY2025) is the most important financial story: it reflects durable operating improvement, not one-time items.

---

#### 6. Source Index

| Code | Source |
|------|--------|
| S1 | XBRL: SEC EDGAR CIK 0001167379; StockAnalysis.com balance sheet + cash flow |
| S2 | Alcon 20-F FY2024; press releases disclosing core EPS; StockAnalysis consensus data |
| S3 | Short thesis review: BofA analyst notes (via Tavily); competitive intelligence; no formal short report on file |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ALC/fundamental

## Navigation

- Overview: /stocks/ALC
- Financials (this page): /stocks/ALC/financials
- Thesis: /stocks/ALC/thesis
- Investment Memo: /stocks/ALC/memo
- Coverage universe: /stocks